Possibly. Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone. Studies showing an increase in catastrophic events had serious methodologic issues. A large surveillance study is ongoing.
|Original language||English (US)|
|Number of pages||2|
|Journal||The Journal of family practice|
|State||Published - Jun 1 2015|